Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An epidemiologist's viewpoint on screening

C A Parkes1

  • 1Department of Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, St Bartholomew's Hospital Medical College, London.

Cancer Surveys
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility study of a randomised trial of ovarian cancer screening among the general population.

Journal of medical screeningยท1994
See all related articles

Prostate cancer screening tests like DRE and PSA show promise but require more research. Current data suggests screening could significantly reduce mortality, but ad hoc screening is discouraged until further evidence is available.

Area of Science:

  • Oncology
  • Public Health
  • Diagnostic Medicine

Background:

  • Prostate cancer is a significant health concern globally, with high incidence and mortality rates.
  • Current screening methods include Digital Rectal Exam (DRE), Transrectal Ultrasound (TRUS), and Prostate-Specific Antigen (PSA) blood tests.

Purpose of the Study:

  • To evaluate the performance of DRE, TRUS, and PSA screening tests for prostate cancer.
  • To assess the potential impact of prostate cancer screening on mortality rates.

Main Methods:

  • Aggregated data analysis from studies on DRE, TRUS, and PSA test performance.
  • Estimation of detection rates (DR) and false positive rates (FPR) for each screening method.
  • Modeling the potential mortality reduction based on increased early-stage diagnosis.

Related Experiment Videos

Main Results:

  • DRE and PSA tests show promising performance metrics (e.g., DRE: 68% DR, 5% FPR; PSA: 79% DR, 8% FPR).
  • Observed cancer prevalence in studies was higher than in the general population, potentially inflating performance estimates.
  • Screening could reduce mortality by 48% (approx. 1500 lives/year) if it increased localized diagnoses to 100%.

Conclusions:

  • While DRE and PSA show potential, further research is essential to validate their effectiveness and safety.
  • A randomized controlled trial is needed to definitively determine if prostate cancer screening reduces mortality.
  • Ad hoc screening is not recommended at this time due to insufficient evidence and potential overestimation of benefits.